Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3602MR)

This product GTTS-WQ3602MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3602MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8618MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ8678MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ6927MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ14082MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ8455MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ2534MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ12204MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ7575MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW